HARBIN, China, April 29 /Xinhua-PRNewswire-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or "the Company"), a leading pharmaceutical company in the People's Republic of China ("PRC"), today announced its successful participation in the 103rd China Import and Export Fair in Guangzhou, China from April 15th to April 30th 2008.
With more than a fifty-year history, the China Import and Export Fair is one of the most well attended trade shows in China, and it boasts the widest array of products from around the globe. This year, there were more than 300,000 people attending the trade show, representing industries as diverse as clothing, chemicals, computers, auto, foods, electronics, energy, appliances, drinks, pharmaceuticals and machinery. Among the 300,000 attendees, about 200,000 came from 213 countries outside of China. The China Import and Export Fair is considered by many businesses to be the most effective exhibition in China, as it generates a high volume of transactions.
At the trade show, Renhuang presented its leading branded drugs Acanthopanax (Siberian Ginseng) and Tianma Headache Relief Pills. Acanthopanax, extracted from natural plants for the treatment of sleep disorders and depression, is highly popular with the overseas distributors. The Company's booth attracted more than 1,500 visitors. Among them, over 500 distributors have expressed strong interest in licensing and distributing the Company's products. The Company is in discussion with about 100 distributors as potential distribution partners and to date has already signed three letters of intent for distribution collaborations.
"We are excited that our products were so highly regarded at the China Import and Export Fair. This speaks to our strong brand name recognition and strong worldwide customer demand. We intend to continue with our strategy of developing high quality products and expanding our presence in the overseas market," said Mr. Shao-ming Li, Chairman and CEO of Renhaung Pharmaceuticals, Inc.
About Renhuang Pharmaceuticals, Inc.
Founded in 1996, Renhuang Pharmaceuticals, Inc, produces Western, traditional Chinese medicines (TCM), and branded pharmaceuticals, using its GMP-certified facilities in China. The Company's GMP-certified manufacturing facilities, containing cutting-edge technologies and advance equipment, are capable of producing a many as 200 types of pharmaceuticals. Additionally, Renhuang distributes raw materials and finished pharmaceuticals using its broad distribution channels and third party distributors throughout China. The Company's distribution network includes over 3,000 sales representatives in 70 sales centers across 24 districts, covering over 50% of the greater China. The Company also exports its products to Russia and Southeast Asia. For more information, visit http://www.renhuang.com .
Safe Harbor Statement
This press release contains certain statements that may include 'forward-looking statements' as defined in the Securities Act of 1933, and the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included herein are 'forward-looking statements'. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release.
The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with and available from the Securities and Exchange Commission. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
SOURCE Renhuang Pharmaceuticals, Inc.